Key Points
- Perspective Therapeutics CAO Jonathan Robert Hunt bought 11,000 shares on Nov. 13 at an average price of $2.03, increasing his stake by 22.54% to 59,800 shares (about $121,394).
- Wall Street sentiment is broadly positive with a consensus "Buy" rating and an average price target of $11.89, including analyst targets in the $10–$14 range.
- The company reported a quarterly EPS miss (loss of $0.35 vs. -$0.33 expected), has extremely negative margins and minimal revenue, indicating continued financial risk despite analyst optimism.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) CAO Jonathan Robert Hunt bought 11,000 shares of the company's stock in a transaction dated Thursday, November 13th. The stock was bought at an average cost of $2.03 per share, with a total value of $22,330.00. Following the acquisition, the chief accounting officer directly owned 59,800 shares of the company's stock, valued at approximately $121,394. The trade was a 22.54% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Perspective Therapeutics Price Performance
Shares of Perspective Therapeutics stock opened at $2.21 on Tuesday. The firm's 50 day moving average is $3.22 and its 200 day moving average is $3.32. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $7.95. The company has a quick ratio of 15.09, a current ratio of 15.09 and a debt-to-equity ratio of 0.01.
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.02). The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million. Perspective Therapeutics had a negative net margin of 7,688.50% and a negative return on equity of 33.37%. Sell-side analysts expect that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on CATX shares. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research report on Friday, October 3rd. BTIG Research assumed coverage on Perspective Therapeutics in a research note on Friday, October 10th. They issued a "buy" rating and a $14.00 price objective for the company. Finally, Wedbush reiterated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, November 11th. Four research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $11.89.
View Our Latest Report on CATX
Hedge Funds Weigh In On Perspective Therapeutics
Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Perspective Therapeutics by 5.0% in the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company's stock worth $11,792,000 after acquiring an additional 163,532 shares during the period. Affinity Asset Advisors LLC boosted its stake in shares of Perspective Therapeutics by 71.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock valued at $4,738,000 after purchasing an additional 924,196 shares during the last quarter. Nicholson Wealth Management Group LLC increased its position in shares of Perspective Therapeutics by 0.3% during the second quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company's stock worth $5,553,000 after buying an additional 5,000 shares during the period. Geode Capital Management LLC raised its stake in Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company's stock worth $4,758,000 after buying an additional 188,887 shares during the last quarter. Finally, Nuveen LLC bought a new position in Perspective Therapeutics during the first quarter worth $2,647,000. 54.66% of the stock is currently owned by institutional investors.
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
